Dipanjan Pan | |
---|---|
Nationality | American |
Occupation(s) | Academic Entrepreneur |
Academic background | |
Alma mater | Indian Institute of Technology |
Academic advisors | Karen L. Wooley |
Academic work | |
Institutions |
Washington University in St. Louis
University of Illinois at Urbana-Champaign |
Dipanjan Pan is an Indian American academic who is the Dorothy Foehr Huck & J. Lloyd Huck Chair Professor in Nanomedicine at Pennsylvania State University. [1]
Dipanjan Pan was born in India. [2] He obtained his doctoral degree from the Indian Institute of Technology and subsequently joined Washington University in St. Louis. [3] There, he collaborated with Karen L. Wooley on investigating the utilization of self-assembled polymeric nanoparticles for targeted drug delivery applications. [3]
Pan started his career in 2005 as an intellectual property analyst in chemistry at General Electric's John F. Welch Technology Centre. [4]
In 2007, he joined the Washington University School of Medicine in Saint Louis as a research instructor. [4] [5] In 2010, he became an assistant professor in medicine and served until 2013, contributing to the field of cardiovascular research. [4] [6]
In 2013, Pan joined the University of Illinois Urbana-Champaign as an assistant professor. [4]
In 2014, Pan co-founded InnSight Technology, a preclinical company, along with Leanne Labriola. [7] Two years later, in 2016, he co-founded KaloCyte, a company that has developed an artificial blood called Erythromer, with Allan Doctor and Philip Spinella. [8] [9] He has served as a professor of radiology in the school of medicine, and professor of chemical and biochemical and environmental engineering at the University of Maryland, Baltimore County. [10] [11]
Pan is the current head of the Pan Laboratory for Materials in Medicine. [12]
His research focuses on the development and application of nanoscale materials and techniques for the diagnosis and treatment of various diseases, particularly cancer and cardiovascular disorders. [3]
In 2014, Pan and his team reported a novel method for inhibiting cancer cell growth using nanotechnology, as detailed in a paper presented at the American Chemical Society conference. [13] The preliminary research demonstrated success in impeding breast cancer and melanoma cell growth in laboratory settings by delivering a synthetic compound mimicking venom from bees, snakes, and scorpions. [13] [14]
In 2015, Pan, Leanne Labriola, and other team members developed a portable sensor named OcuCheck that assesses ocular injuries through the quantification of vitamin C concentration in a patient's tears at the University of Illinois. [15]
In 2018, Pan and other researchers at the University of Illinois created a gel utilizing gold nanoparticles which has the capability to rapidly detect ocular trauma. [16]
In 2020, Pan and his team initiated the development of rapid tests for detecting COVID-19. [17] [18] Within six months, they created their first test, followed by four more by the end of 2021. [19] Three tests, including the Antisense test, have been licensed for commercialization and registered with the Food and Drug Administration. [19] Later, he founded a company called VitruVian Bio to further develop the test for commercial applications. [20] [21]
In 2023, Dipanjan Pan and his research team developed the first rapid test for monkeypox, as reported in the journal Advanced Functional Materials. [22] It uses a selective molecular sensor that can detect the virus within minutes. [22] The method employs nanomaterial heterostructures, consisting of zero-dimensional spherical gold nanoparticles and two-dimensional hafnium disulfide nanoplatelets, as building blocks to create a platform technology capable of detecting trace amounts of genetic material in biological samples. [22]
Dipanjan Pan | |
---|---|
Nationality | American |
Occupation(s) | Academic Entrepreneur |
Academic background | |
Alma mater | Indian Institute of Technology |
Academic advisors | Karen L. Wooley |
Academic work | |
Institutions |
Washington University in St. Louis
University of Illinois at Urbana-Champaign |
Dipanjan Pan is an Indian American academic who is the Dorothy Foehr Huck & J. Lloyd Huck Chair Professor in Nanomedicine at Pennsylvania State University. [1]
Dipanjan Pan was born in India. [2] He obtained his doctoral degree from the Indian Institute of Technology and subsequently joined Washington University in St. Louis. [3] There, he collaborated with Karen L. Wooley on investigating the utilization of self-assembled polymeric nanoparticles for targeted drug delivery applications. [3]
Pan started his career in 2005 as an intellectual property analyst in chemistry at General Electric's John F. Welch Technology Centre. [4]
In 2007, he joined the Washington University School of Medicine in Saint Louis as a research instructor. [4] [5] In 2010, he became an assistant professor in medicine and served until 2013, contributing to the field of cardiovascular research. [4] [6]
In 2013, Pan joined the University of Illinois Urbana-Champaign as an assistant professor. [4]
In 2014, Pan co-founded InnSight Technology, a preclinical company, along with Leanne Labriola. [7] Two years later, in 2016, he co-founded KaloCyte, a company that has developed an artificial blood called Erythromer, with Allan Doctor and Philip Spinella. [8] [9] He has served as a professor of radiology in the school of medicine, and professor of chemical and biochemical and environmental engineering at the University of Maryland, Baltimore County. [10] [11]
Pan is the current head of the Pan Laboratory for Materials in Medicine. [12]
His research focuses on the development and application of nanoscale materials and techniques for the diagnosis and treatment of various diseases, particularly cancer and cardiovascular disorders. [3]
In 2014, Pan and his team reported a novel method for inhibiting cancer cell growth using nanotechnology, as detailed in a paper presented at the American Chemical Society conference. [13] The preliminary research demonstrated success in impeding breast cancer and melanoma cell growth in laboratory settings by delivering a synthetic compound mimicking venom from bees, snakes, and scorpions. [13] [14]
In 2015, Pan, Leanne Labriola, and other team members developed a portable sensor named OcuCheck that assesses ocular injuries through the quantification of vitamin C concentration in a patient's tears at the University of Illinois. [15]
In 2018, Pan and other researchers at the University of Illinois created a gel utilizing gold nanoparticles which has the capability to rapidly detect ocular trauma. [16]
In 2020, Pan and his team initiated the development of rapid tests for detecting COVID-19. [17] [18] Within six months, they created their first test, followed by four more by the end of 2021. [19] Three tests, including the Antisense test, have been licensed for commercialization and registered with the Food and Drug Administration. [19] Later, he founded a company called VitruVian Bio to further develop the test for commercial applications. [20] [21]
In 2023, Dipanjan Pan and his research team developed the first rapid test for monkeypox, as reported in the journal Advanced Functional Materials. [22] It uses a selective molecular sensor that can detect the virus within minutes. [22] The method employs nanomaterial heterostructures, consisting of zero-dimensional spherical gold nanoparticles and two-dimensional hafnium disulfide nanoplatelets, as building blocks to create a platform technology capable of detecting trace amounts of genetic material in biological samples. [22]